Regulatory Roundup: EMA Releases Genetic Variability Guideline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: EMA Releases Genetic Variability Guideline

ePT--the Electronic Newsletter of Pharmaceutical Technology

EMA has released a guideline on how to integrate studying the role of genetic variability between patients during the development of medicines. The guideline, effective August 2012, clarifies the requirements for the analysis of the effect of genetic variability on the way the human body handles medicines. The guideline addresses when pharmacogenetic studies should be performed, how these studies should be designed and carried out, how the clinical impact of genetic differences between patients should be evaluated, how dosing or treatment recommendations for genetic subpopulations should be studied, consequences for treatment recommendations and labeling, and the impact of interactions between medicines and of impaired or immature organ function.

The US Pharmacopeia is bringing together regulators, manufacturers, and other stakeholders in global public health for the 11th IPC-USP Science & Standards Symposium on February 22–23 in Mumbai. This year’s Symposium will focus on two important areas for India’s pharmaceutical sector—global quality standards for biologic medicines and supply chain management, according to USP. “The meeting is part of a continuing USP effort with the government of India generally and the IPC specifically to promote access to good quality medicines—not only those being exported but also those intended for the people of India,” says a USP press release on the meeting. For details, visit the USP registration site.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here